NCT07241221Recruiting
Antenatal Myo-inositol Supplementation in Pre-existing Diabetes
Antenatal Myo-inositol Supplementation in Pre-existing Diabetes to Promote Normal Neonatal Outcomes
Source: ClinicalTrials.gov · Last updated 9 Dec 2025
Brief summary (registry, in English)
This feasibility pilot study aims to gather data that can guide the design of a larger, more comprehensive trial to establish the effects of myo-inositol supplementation on supporting healthy outcomes in pregnancies complicated by Type 2 Diabetes Mellitus (T2DM). It seeks to assess myo-inositol's potential to support fetal and neonatal health, and optimise maternity outcomes as a complementary approach and adjuvant to existing diabetes mellitus therapies, as well as investigate the underlying biological mechanisms.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 182 (estimated)
- First submitted
- 18 Sept 2025
- Start date
- Dec 2025
- Primary completion date
- 31 Aug 2028
- Lead sponsor
- National University Hospital, Singapore
- Diseases
- Type 2 diabetes
- NCT number
- NCT07241221
What you commit to
- Study type: Interventional
- Planned participants: 182
- From Dec 2025 to the primary completion date, 31 Aug 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe allergy to food items requiring carriage of an Epipen at all times
Other
- Known or suspected fetal aneuploidy or genetic/structural anomaly
Who the study is looking for
- Pregnant women aged 21 years to 45 years old at the time of recruitment
- Ongoing, viable, singleton intrauterine pregnancy
- Between 12+0 days-16+6 days weeks' gestation at recruitment
- T2DM diagnosed by a documented 75g Oral Glucose Tolerance Test (OGTT) showing a fasting glucose of \>7 mmol/L or 2h glucose \>11.1 mmol/L, or an HbA1C \>6.5%, either prior to pregnancy or during the first 16 weeks of the index pregnancy
- Intend to receive antenatal care and give birth at NUH
- Willing to provide written, informed consent
- Able to swallow capsules and comply with trial procedures
Age in the registry: 21 years to 45 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National University Hospital Coordinator of this site? Confirm its status | Singapore | Singapore | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.